Learn steps health care systems can take to better prepare for future disruptions.
Register now for our Sept. 9 webcast to hear leading clinicians and researchers discuss vulnerabilities within our nation’s public health and healthcare systems that contributed to the decrease in cancer screening and care during the pandemic, as well as the further exacerbation of inequities.
Panelists will also explore and showcase concrete action steps that can be taken to build resilience in our public health and health care systems. These tangible solutions will not only prepare us for any ongoing or future disruptions to the delivery of cancer screening, diagnostics, and care, but will also aid in appropriately addressing persistent disparities.
This Issue Hub #2 is free and open to all, and will run from 1 to 2:30 p.m. EST.
Discussion objectives include:
- Understand where there are weaknesses and/or vulnerabilities in the U.S. health care system that worsened outcomes in cancer screening and care during the COVID-19 pandemic.
- Identify steps for strengthening our health care systems to be better prepared and equipped to address future disruptions (e.g. pandemics, natural disasters, etc.).
- Learn how some systems have successfully navigated cancer screening and care during the pandemic and improved outcomes.
The American Cancer Society (ACS) National Consortium is developing bold but sensible recommendations toward the safe and equitable recovery of cancer screening and care during the COVID-19 pandemic.
On June 1, the consortium welcomed over 300 attendees to participate on our inaugural Issue Hub titled “Accelerating What We Know Works in Cancer Screening and Care.” Read more about that here. A recording of the June Issue Hub is available here.
A third Issue Hub will be scheduled later this year.
About the ACS National Consortium
ACS and ACS CAN have organized mission priorities and program work to effectively respond to consequences from the COVID-19 pandemic on cancer screening and care. The National Consortium, which focuses on accelerating, strengthening, and mobilizing, is one component of this initiative. It is an issue-focused, time-bound partnership that is dedicated to the acceleration of a national response to the COVID-19 pandemic in relation to its detrimental impact on our collective progress in cancer screening and care across the U.S. Our overall return to screening effort is supported by Genentech, Pfizer, Merck, and the National Football League.